Diabetes pill may halt deadly liver scarring in hepatitis b
NCT ID NCT05147090
Summary
This study is testing if a common diabetes medication, empagliflozin, can prevent or slow the progression of liver scarring (fibrosis and cirrhosis) in people with chronic hepatitis B. The trial involves 106 patients who are already taking standard antiviral drugs but still have significant liver scarring. Participants will take either empagliflozin or a placebo pill daily for three years while doctors measure changes in liver stiffness using special scans.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CIRRHOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The University of Hong Kong/Queen Mary Hospital
Hong Kong, Hong Kong, China, 852, Hong Kong
Conditions
Explore the condition pages connected to this study.